Please assess the completion status of the following clinical trial:

Trial Title: A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory CLL, NHL or MM~* ECOG Performance Status of 0, 1, or 2~* Adequate organ function (protocol defined)~* ECG without evidence of clinically significant ventricular arrhythmias~Exclusion Criteria:~* AIDS-related lymphoma~* Subjects with NHL who present exclusively with non-measurable lesions~* Subjects with MM who have non-secretory and/or non-measurable disease~* Recent anticancer therapy (chemotherapy, radiotherapy, and/or biotherapy)within four weeks prior to starting treatment~* Evidence of pulmonary fibrosis~* Other concurrent malignancy~* Uncontrolled concurrent illness~* Receiving chronic, systemically administered steroids~* Known hypersensitivity to nucleoside analogues

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GS-9219 (Type: EXPERIMENTAL): Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m\^2) until determination of the maximum tolerated dose (MTD)

Based on this trial design, predict the completion outcome and termination type (if applicable).